MEDTRONIC CAPSURE EPI EPICARDIAL STEROID-ELUTING PACING LEAD APPROVABLE WITH CONDITIONS, PANEL FINDS; POSTMARKET STUDY OF 50-60 ADULTS RECOMMENDED
This article was originally published in The Gray Sheet
Medtronic's CapSure EPI epicardial steroid-eluting pacing lead is approvable with conditions for adult and pediatric patients in whom transvenous leads cannot be used, FDA's Circulatory System Devices Panel concluded at a July 15 meeting in Rockville, Maryland. The panel agreed that the lead (model 4965) can be used for bradycardia pacing in pediatric patients with anatomy too small to accommodate transvenous leads and in adults with conditions that preclude access with a transvenous system.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.